Black Diamond Therapeutics (NASDAQ:BDTX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Black Diamond Therapeutics (NASDAQ:BDTX) in a research report report published on Wednesday, Benzinga reports. HC Wainwright currently has a $11.00 price target on the stock.

A number of other brokerages have also recently weighed in on BDTX. Wedbush restated an “outperform” rating and set a $16.00 price objective on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Raymond James started coverage on shares of Black Diamond Therapeutics in a research note on Wednesday, July 31st. They issued an “outperform” rating and a $20.00 price target for the company. Finally, Piper Sandler increased their price objective on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, September 23rd.

Black Diamond Therapeutics Stock Performance

Black Diamond Therapeutics stock opened at $3.29 on Wednesday. Black Diamond Therapeutics has a one year low of $1.62 and a one year high of $7.66. The company has a 50-day simple moving average of $4.21 and a 200-day simple moving average of $5.02. The firm has a market capitalization of $185.90 million, a P/E ratio of -2.47 and a beta of 2.51.

Black Diamond Therapeutics (NASDAQ:BDTX) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.09. As a group, sell-side analysts forecast that Black Diamond Therapeutics will post -1.44 earnings per share for the current year.

Institutional Investors Weigh In On Black Diamond Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. bought a new stake in shares of Black Diamond Therapeutics in the 3rd quarter worth approximately $68,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Black Diamond Therapeutics in the first quarter valued at $82,000. SG Americas Securities LLC acquired a new stake in shares of Black Diamond Therapeutics during the 2nd quarter valued at $108,000. Algert Global LLC bought a new stake in shares of Black Diamond Therapeutics during the 2nd quarter worth $133,000. Finally, Rhumbline Advisers grew its holdings in shares of Black Diamond Therapeutics by 10,334.3% in the 2nd quarter. Rhumbline Advisers now owns 46,850 shares of the company’s stock worth $218,000 after acquiring an additional 46,401 shares during the last quarter. 95.47% of the stock is owned by institutional investors and hedge funds.

About Black Diamond Therapeutics

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.